LKLauren E. Kass

Lauren E. Kass

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lauren E. Kass has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • Shawn D. Hingtgen

    Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, USA

    3 shared publications
  • Jillian L. Perry

    Division of Pharmacoengineering and Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA

    2 shared publications
  • Morrent Thang

    Division of Pharmacoengineering and Molecular Pharmaceutics UNC Eshelman School of Pharmacy The University of North Carolina at Chapel Hill 4212 Marsico Hall, 125 Mason Farm Road Chapel Hill NC 27599 USA

    2 shared publications
  • Yu Zhang

    Division of Pharmacoengineering and Molecular Pharmaceutics UNC Eshelman School of Pharmacy The University of North Carolina at Chapel Hill 4212 Marsico Hall, 125 Mason Farm Road Chapel Hill NC 27599 USA

    2 shared publications
  • Abigail Carey‐Ewend

    Division of Pharmacoengineering and Molecular Pharmaceutics UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill Chapel Hill North Carolina USA

    1 shared publication
  • Addis Tessema

    Department of Chemistry, UNC College of Arts and Sciences The University of North Carolina at Chapel Hill Chapel Hill North Carolina USA

    1 shared publication

Latest Publications

  • Open Access

    Characterization of a Bioprinted Anticancer Cell Therapy System Generated with Continuous Liquid Interface Production

    by Lauren Kass, Ike Keku, Yu Zhang, Justin Forbes, Morrent Thang, Jillian Perry, Shawn Hingtgen

    Anticancer cell therapies have remarkable clinical potential yet fail to reach the clinic due to poor delivery. 3D bioprinting (3DBP) can be leveraged for generating cell therapy delivery devices, where the biomaterial system acts as a protective matrix to stabilize cells after implantation. Continuous liquid interface production (CLIP), an additive manufacturing technology, has several unique features that make it a suitable platform for 3DBP of cell‐laden scaffolds. However, the feasibility CLIP bioprinting and efficacy of CLIP‐bioprinted cell/matrix therapies have not yet been explored. In this work, we demonstrate the utility of CLIP for cell therapy 3DBP with a simple gelatin methacrylate‐based resin and anticancer drug‐secreting fibroblasts as a model therapy against recurrent glioblastoma. We demonstrate that CLIP enables rapid, consistent production of cell‐laden scaffolds, and cells maintain their viability and tumor‐killing efficacy in vitro post‐printing. Importantly, we proved that bioprinted cells survive longer in vivo than directly injected cells, and that this effect may correspond to better survival outcomes in a mouse model of glioblastoma resection. This study is the first to utilize CLIP for 3DBP of composite devices containing anticancer cell therapies, providing a crucial foundation for developing highly refined cell therapy delivery devices in the future.


  • Open Access

    Development of a biocompatible 3D hydrogel scaffold using continuous liquid interface production for the delivery of cell therapies to treat recurrent glioblastoma

    by Lauren Kass, Morrent Thang, Yu Zhang, Cathleen DeVane, Julia Logan, Addis Tessema, Jillian Perry, Shawn Hingtgen

    Glioblastoma (GBM) is the most common primary malignant brain tumor diagnosed in adults, carrying with it an extremely poor prognosis and limited options for effective treatment. Various cell therapies have emerged as promising candidates for GBM treatment but fail in the clinic due to poor tumor trafficking, poor transplantation efficiency, and high systemic toxicity. In this study, we design, characterize, and test a 3D‐printed cell delivery platform that can enhance the survival of therapeutic cells implanted in the GBM resection cavity. Using continuous liquid interface production (CLIP) to generate a biocompatible 3D hydrogel, we demonstrate that we can effectively seed neural stem cells (NSCs) onto the surface of the hydrogel, and that the cells can proliferate to high densities when cultured for 14 days in vitro. We show that NSCs seeded on CLIP scaffolds persist longer than freely injected cells in vivo, proliferating to 20% higher than their original density in 6 days after implantation. Finally, we demonstrate that therapeutic fibroblasts seeded on CLIP more effectively suppress tumor growth and extend survival in a mouse model of LN229 GBM resection compared to the scaffold or therapeutic cells alone. These promising results demonstrate the potential to leverage CLIP to design hydrogels with various features to control the delivery of different types of cell therapies. Future work will include a more thorough evaluation of the immunological response to the material and improvement of the printing resolution for biocompatible aqueous resins.


  • Open Access

    Use of FLOSEAL® as a scaffold and its impact on induced neural stem cell phenotype, persistence, and efficacy

    by Hunter N. Bomba, Abigail Carey‐Ewend, Kevin T. Sheets, Alain Valdivia, Morgan Goetz, Ingrid A. Findlay, Alison Mercer‐Smith, Lauren E. Kass, Simon Khagi, Shawn D. Hingtgen

    Induced neural stem cells (iNSCs) have emerged as a promising therapeutic platform for glioblastoma (GBM). iNSCs have the innate ability to home to tumor foci, making them ideal carriers for anti-tumor payloads. However, the in vivo persistence of iNSCs limits their therapeutic potential. We hypothesized that by encapsulating iNSCs in the FDA-approved, hemostatic matrix FLOSEAL®, we could increase their persistence and, as a result, therapeutic durability. Encapsulated iNSCs persisted for 95 days whereas iNSCs injected into the brain parenchyma persisted only 2 weeks in mice. Two orthotopic GBM tumor models were used to test the efficacy of encapsulated iNSCs. In the GBM8 tumor model, mice that received therapeutic iNSCs encapsulated in FLOSEAL® survived 30 to 60 days longer than mice that received non-encapsulated cells. However, the U87 tumor model showed no significant differences in survival between these two groups, likely due to the more solid and dense nature of the tumor. Interestingly, the interaction of iNSCs with FLOSEAL® appears to down-regulate some markers of proliferation, anti-apoptosis, migration, and therapy which could also play a role in treatment efficacy and durability. Our results demonstrate that while FLOSEAL® significantly improves iNSC persistence, this alone is insufficient to enhance therapeutic durability.


  • Nanocarrier‐hydrogel composite delivery systems for precision drug release

    by Lauren E. Kass, Juliane Nguyen

    Hydrogels are a class of biomaterials widely implemented in medical applications due to their biocompatibility and biodegradability. Despite the many successes of hydrogel‐based delivery systems, there remain challenges to hydrogel drug delivery such as a burst release at the time of administration, a limited ability to encapsulate certain types of drugs (i.e., hydrophobic drugs, proteins, antibodies, and nucleic acids), and poor tunability of geometry and shape for controlled drug release. This review discusses two main important advances in hydrogel fabrication for precision drug release: first, the incorporation of nanocarriers to diversify their drug loading capability, and second, the design of hydrogels using 3D printing to precisely control drug dosing and release kinetics via high‐resolution structures and geometries. We also outline ongoing challenges and discuss opportunities to further optimize drug release from hydrogels for personalized medicine.This article is categorized under: Nanotechnology Approaches to Biology > Nanoscale Systems in Biology Therapeutic Approaches and Drug Discovery > Emerging Technologies